Cycle control, tolerability, and satisfaction among women switching from 30-35 μg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 μg ethinyl estradiol-containing oral contraceptive Ortho TrimCyclen® LO

被引:0
|
作者
Poindexter, AN
Burkman, R
Fisher, AC
LaGuardia, KD
机构
[1] OrthoMcNeil Pharmaceut Inc, Womens Hlth Care, Raritan, NJ 08869 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Baystate Med Ctr, Springfield, MA USA
关键词
contraception; cycle control; estrogen; norgestimate; satisfaction;
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective-To determine cycle control, tolerability, and satisfaction among women (aged 18-45) switching from oral contraceptives (OCs) containing 30-35 mug ethinyl estradiol (EE) to Ortho Tri-Cyclen(R) LO (norgestimate 180/215/250 mug/EE 25 mug) and Loestrin(R) Fe 1/20 (norethindrone acetate I mg/EE 20 mug). Design-A subset of patients from a study comparing Ortho Tri-Cyclen LO (N = 864) with Loestrin Fe 1/20 (N = 565) was analyzed. The subset was defined as those who had taken a 30-35 mug EE-containing OC within 60 days of study start. The total number of cycles of exposure for the subset was 6,054 for Ortho Tri-Cyclen LO and 3,814 for Loestrin Fe 1/20. Additional analyses evaluated switchovers from Ortho Tri-Cyclen(R) to Ortho Tri-Cyclcn LO (N = I 11). Main Outcome Measures-Cycle control was assessed by daily diary cards reporting the frequency, severity, and duration of bleeding/spotting. Discontinuation rates due to adverse events (AEs) were considered to reflect tolerability. Satisfaction was evaluated by questionnaire. Results-The proportion of cycles in which subjects experienced breakthrough bleeding and/or spotting was significantly lower with Ortho Tri-Cyclen LO than Loestrin Fe 1/20. Discontinuations due to AEs and serious AEs were comparable for Ortho Tri-Cyclen LO (3.4% and 0.6%, respectively) and Loestrin Fe 1/20 (3.2% and 0.7%, respectively). More women on Ortho Tri-Cyclen LO versus Loestrin Fe 1/20 were very or somewhat satisfied at Cycle 6 (86% vs. 81.1%; P < 0.05) and last visit (81.6% vs. 78.1%; P < 0.05). At Cycle 6, 89.3% of Ortho Tri-Cyclen to Ortho Tri-Cyclen LO switchovers were very or somewhat satisfied, and 72.6% desired to continue taking Ortho Tri-Cyclen LO after study conclusion. Conclusions-Switchovers from OCs containing 30-35 mug EE to Ortho Tri-Cyclen LO had excellent cycle control and tolerability, and were satisfied.
引用
收藏
页码:163 / 172
页数:10
相关论文
共 42 条
  • [21] Modulation of ovarian function by an oral contraceptive containing 30 mu g ethinyl estradiol in combination with 2.00 mg dienogest
    Spona, J
    Feichtinger, W
    Kindermann, C
    Moore, C
    Mellinger, U
    Walter, F
    Graser, T
    [J]. CONTRACEPTION, 1997, 56 (03) : 185 - 191
  • [22] Effect of oral contraceptives containing 20 and 35 μg ethinyl estradiol on urinary prostacyclin and thromboxane metabolite levels in smokers and nonsmokers
    Stanczyk, FZ
    Ploszaj, S
    Gentzschein, E
    Qian, DJ
    Mishell, DR
    [J]. CONTRACEPTION, 1999, 59 (01) : 17 - 23
  • [23] DOUBLE-BLIND COMPARISON OF 2 ORAL-CONTRACEPTIVES CONTAINING 50 MU-G AND 30 MU-G ETHINYL ESTRADIOL
    DIONNE, P
    VICKERSON, F
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1974, 16 (04): : 281 - 288
  • [24] Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 20 μg ethinyl estradiol and 150 μg desogestrel
    Endrikat, J
    Cronin, M
    Gerlinger, C
    Ruebig, A
    Schmidt, W
    Düsterberg, B
    [J]. CONTRACEPTION, 2001, 64 (03) : 201 - 207
  • [25] A MULTICENTER EFFICACY AND SAFETY STUDY OF AN ORAL-CONTRACEPTIVE CONTAINING 150-MU-G DESOGESTREL AND 30-MU-G ETHINYL ESTRADIOL
    WALLING, M
    [J]. CONTRACEPTION, 1992, 46 (04) : 313 - 326
  • [26] Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate
    Markantes, George
    Saltamavros, Alexandros D.
    Vervita, Vasiliki
    Armeni, Anastasia K.
    Karela, Anastasia
    Adonakis, George
    Decavalas, George
    Georgopoulos, Neoklis A.
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (12) : 971 - 977
  • [27] Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol
    Nyberg, Sigrid
    [J]. CONTRACEPTION, 2013, 87 (06) : 773 - 781
  • [28] Serum folate and Vitamin B12 levels in women using modern oral contraceptives (OC) containing 20 μg ethinyl estradiol
    Sütterlin, MW
    Bussen, SS
    Rieger, L
    Dietl, J
    Steck, T
    [J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2003, 107 (01): : 57 - 61
  • [29] Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure
    Recep Yildizhan
    Begum Yildizhan
    Ertan Adali
    Pinar Yoruk
    Fatih Birol
    Necdet Suer
    [J]. Archives of Gynecology and Obstetrics, 2009, 280 : 255 - 261
  • [30] Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure
    Yildizhan, Recep
    Yildizhan, Begum
    Adali, Ertan
    Yoruk, Pinar
    Birol, Fatih
    Suer, Necdet
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2009, 280 (02) : 255 - 261